FDA to grant breakthrough drug status to Glaxo’s drisapersen
The Breakthrough Therapy designation has been granted by the regulator, after vetting the results from the Phase II Study (DMD114117), submitted in April at Cold Spring Harbor. The
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.